The Wall Street Journal-20080116-GlaxoSmithKline PLC- EU Approves Marketing Of Allergy Medication

Return to: The_Wall_Street_Journal-20080116

GlaxoSmithKline PLC: EU Approves Marketing Of Allergy Medication

Full Text (86  words)

Roundup

GlaxoSmithKline PLC said Avamys, a once-daily spray to treat the symptoms of allergic rhinitis, received marketing authorization from the European Commission, the European Union's executive arm. The decision was expected after the European Medicines Agency issued a positive opinion on Avamys in October. Avamys received U.S. approval under the brand name Veramyst in April. Allergic rhinitis is a collection of symptoms, predominantly in the nose and eyes, caused by dust, dander or pollen. When pollen causes the symptoms, the condition is commonly called hay fever.